<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Keating SM</submitter><funding>National Institute of Allergy and Infectious Diseases</funding><funding>Eunice Kennedy Shriver National Institute of Child Health and Human Development</funding><funding>Clinical and Translational Science Institute, University of California, San Francisco</funding><funding>NICHD NIH HHS</funding><funding>NIDDK NIH HHS</funding><funding>NCRR NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>Biostatistics Core of the UCSF Liver Center</funding><pagination>e0181004</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5597129</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(9)</volume><pubmed_abstract>Hepatitis C virus infection induces inflammation and while it is believed that HIV co-infection enhances this response, HIV control may reduce inflammation and liver fibrosis in resolved or viremic HCV infection. Measurement of systemic biomarkers in co-infection could help define the mechanism of inflammation on fibrosis and determine if HIV control reduces liver pathology. A nested case-control study was performed to explore the relationship of systemic biomarkers of inflammation with liver fibrosis in HCV viremic and/or seropositive women with and without HIV infection. Serum cytokines, chemokines, growth factors and cell adhesion molecules were measured in HIV uninfected (HIV-, n = 18), ART-treated HIV-controlled (ARTc, n = 20), uncontrolled on anti-retroviral therapy (ARTuc, n = 21) and elite HIV controllers (Elite, n = 20). All were HCV seroreactive and had either resolved (HCV RNA-; &lt;50IU/mL) or had chronic HCV infection (HCV RNA+). In HCV and HIV groups, aspartate aminotransferase to platelet ratio (APRI) was measured and compared to serum cytokines, chemokines, growth factors and cell adhesion molecules. APRI correlated with sVCAM, sICAM, IL-10, and IP-10 levels and inversely correlated with EGF, IL-17, TGF-α and MMP-9 levels. Collectively, all HCV RNA+ subjects had higher sVCAM, sICAM and IP-10 compared to HCV RNA-. In the ART-treated HCV RNA+ groups, TNF-α, GRO, IP-10, MCP-1 and MDC were higher than HIV-, Elite or both. In ARTuc, FGF-2, MPO, soluble E-selectin, MMP-9, IL-17, GM-CSF and TGF-α are lower than HIV-, Elite or both. Differential expression of soluble markers may reveal mechanisms of pathogenesis or possibly reduction of fibrosis in HCV/HIV co-infection.</pubmed_abstract><journal>PloS one</journal><pubmed_title>The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study.</pubmed_title><pmcid>PMC5597129</pmcid><funding_grant_id>UO1-AI-34989</funding_grant_id><funding_grant_id>UO1-AI-31834</funding_grant_id><funding_grant_id>U01 AI034989</funding_grant_id><funding_grant_id>P30 AI027763</funding_grant_id><funding_grant_id>U01 AI031834</funding_grant_id><funding_grant_id>U01 AI034994</funding_grant_id><funding_grant_id>U01 AI034993</funding_grant_id><funding_grant_id>U01 AI035004</funding_grant_id><funding_grant_id>UO1-AI-35004</funding_grant_id><funding_grant_id>UO1-AI-42590</funding_grant_id><funding_grant_id>U01 HD032632</funding_grant_id><funding_grant_id>UO1-HD-32632</funding_grant_id><funding_grant_id>UO1-AI-34993</funding_grant_id><funding_grant_id>UO1-AI-34994</funding_grant_id><funding_grant_id>P30 DK026743</funding_grant_id><funding_grant_id>U01 AI042590</funding_grant_id><funding_grant_id>UL1 RR024131</funding_grant_id><pubmed_authors>Greenblatt RM</pubmed_authors><pubmed_authors>Norris PJ</pubmed_authors><pubmed_authors>Dodge JL</pubmed_authors><pubmed_authors>Peters MG</pubmed_authors><pubmed_authors>Keating SM</pubmed_authors><pubmed_authors>Women’s Interagency HIV Study</pubmed_authors><pubmed_authors>Villacres MC</pubmed_authors><pubmed_authors>Heitman J</pubmed_authors><pubmed_authors>French AL</pubmed_authors><pubmed_authors>Latham PS</pubmed_authors><pubmed_authors>Gange SJ</pubmed_authors><pubmed_authors>Glesby MJ</pubmed_authors><pubmed_authors>Edlin BR</pubmed_authors></additional><is_claimable>false</is_claimable><name>The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study.</name><description>Hepatitis C virus infection induces inflammation and while it is believed that HIV co-infection enhances this response, HIV control may reduce inflammation and liver fibrosis in resolved or viremic HCV infection. Measurement of systemic biomarkers in co-infection could help define the mechanism of inflammation on fibrosis and determine if HIV control reduces liver pathology. A nested case-control study was performed to explore the relationship of systemic biomarkers of inflammation with liver fibrosis in HCV viremic and/or seropositive women with and without HIV infection. Serum cytokines, chemokines, growth factors and cell adhesion molecules were measured in HIV uninfected (HIV-, n = 18), ART-treated HIV-controlled (ARTc, n = 20), uncontrolled on anti-retroviral therapy (ARTuc, n = 21) and elite HIV controllers (Elite, n = 20). All were HCV seroreactive and had either resolved (HCV RNA-; &lt;50IU/mL) or had chronic HCV infection (HCV RNA+). In HCV and HIV groups, aspartate aminotransferase to platelet ratio (APRI) was measured and compared to serum cytokines, chemokines, growth factors and cell adhesion molecules. APRI correlated with sVCAM, sICAM, IL-10, and IP-10 levels and inversely correlated with EGF, IL-17, TGF-α and MMP-9 levels. Collectively, all HCV RNA+ subjects had higher sVCAM, sICAM and IP-10 compared to HCV RNA-. In the ART-treated HCV RNA+ groups, TNF-α, GRO, IP-10, MCP-1 and MDC were higher than HIV-, Elite or both. In ARTuc, FGF-2, MPO, soluble E-selectin, MMP-9, IL-17, GM-CSF and TGF-α are lower than HIV-, Elite or both. Differential expression of soluble markers may reveal mechanisms of pathogenesis or possibly reduction of fibrosis in HCV/HIV co-infection.</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017</publication><modification>2025-04-05T14:04:31.596Z</modification><creation>2019-03-27T02:56:13Z</creation></dates><accession>S-EPMC5597129</accession><cross_references><pubmed>28902848</pubmed><doi>10.1371/journal.pone.0181004</doi></cross_references></HashMap>